Cellenkos has received FDA clearance to begin its Phase II clinical trial of CK0801 for the treatment of aplastic anaemia.

If approved, Veradermics' VDPHL01 could become the first hair loss drug to secure the regulatory go-ahead in nearly three decades.

Compass Therapeutics’ stock has dropped by more than 60% after a Phase II/III trial of its biliary tract cancer (BTC) combination therapy met one key secondary endpoint but miss ...

Oruka Therapeutics has reported positive interim data from the ongoing EVERLAST-A Phase IIa trial evaluating ORKA-001 in patients with moderate-to-severe plaque psoriasis.

New data on the pulsed-field ablation (PFA) device class debuts at HRS 2026 as the field catches the eye of several large medtech companies.